Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$237.84 USD

237.84
1,032,669

+0.54 (0.23%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Becton, Dickinson Hits at a 52-Week High: What's Driving It?

Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.

    Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm

    Medtronic (MDT) focuses on initiatives to boost its diabetes business.

      Becton, Dickinson Global Foothold Strong, Recalls Rampant

      Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.

        Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3

        Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.

          Becton Dickinson (BDX) Tops Q3 Earnings and Revenue Estimates

          Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.11% and 0.97%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

            Medical Product Earnings Lineup for Aug 2: ABC, BDX & More

            Strong R&D focus is likely to be the key driver of the Medical Product space in Q2.

              Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

              Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.

                Stock Market News For Jul 12, 2018

                Wall Street closed sharply lower on Wednesday ending its four-day winning streak

                  Stock Market News For Jul 11, 2018

                  U.S. stock markets continues their winning streak for the fourth straight session as all three major indexes ended up in positive territory on Tuesday

                    BD Buys TVA Medical, To Provide Minimally Invasive Procedure

                    The acquisition of TVA Medical will enable Becton, Dickinson (BDX) to treat patients with chronic kidney disease through minimally invasive procedures.

                      Will Flagship Impella Drive Abiomed's (ABMD) Q1 Earnings?

                      Abiomed's (ABMD) first-quarter fiscal 2019 earnings are likely to be driven by an exclusive Impella product line. Intense competition raises concern.

                        Can International Sales Drive Baxter's (BAX) Q2 Earnings?

                        Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.

                          Here's Why You Should Hold on to Becton, Dickinson Stock Now

                          Becton, Dickinson (BDX) gains from strong fundamentals. Recent product recall issues raise concern.

                            Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

                            Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

                              Medical Device Industry Outlook - June 2018

                              The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.

                                Why Is Becton, Dickinson (BDX) Down 2.4% Since its Last Earnings Report?

                                Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Becton, Dickinson (BDX) Beats on Q2 Earnings & Revenues

                                  Becton, Dickinson (BDX) gains on solid segmental performance; raises fiscal 2018 guidance.

                                    What's in Store for DENTSPLY (XRAY) This Earnings Season?

                                    DENTSPLY's (XRAY) CAD/CAM unit is likely to drive the top line in Q1. Product innovations and strong R&D prospects are also likely to drive growth.

                                      Should You Sell Becton, Dickinson (BDX) Before Earnings?

                                      Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

                                        Cigna to Take Over Express Scripts (ESRX) for $67 Billion

                                        Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.

                                          Becton, Dickinson (BDX) Down 1.3% Since Last Earnings Report

                                          Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4

                                            Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.

                                              Patterson Companies (PDCO) Misses on Q3 Earnings, Cuts View

                                              Lower sales and gross-margin compression mars Patterson Companies' (PDCO) results in Q3.

                                                Express Scripts (ESRX) Q4 Earnings Top, Long-Term View Solid

                                                Express Scripts' (ESRX) fourth-quarter 2017 results benefit from rise in patient claims and strong customer retention.

                                                  Mark Vickery headshot

                                                  MedTech's Long-Term Prospects Outweigh Near-Term Risks

                                                  A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.